DILIsym

Durham, United States Founded: 2014 • Age: 12 yrs Acquired By Simulations Plus
Quantitative toxicology software is provided for drug development processes.
Request Access

About DILIsym

DILIsym is a company based in Durham (United States) founded in 2014 was acquired by Simulations Plus in May 2017.. DILIsym operates in a competitive market with competitors including Insitro, HotSpot Therapeutics, TOLREMO therapeutics, Certara and Inpharmatica, among others.

  • Headquarter Durham, United States
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
    $1.5 M (USD), Grant

    Jan 17, 2019

  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    Simulations Plus

    (May 01, 2017)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of DILIsym

  • Total Funding
  • Total Rounds 1
  • Last Round Grant — $1.5M
  • First Round

    (17 Jan 2019)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Jan, 2019 Amount Grant - DILIsym Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in DILIsym

DILIsym has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Simulations Plus and National Institute of Diabetes and Digestive and Kidney Diseases. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Research and health information on diabetes and kidney diseases are provided by NIDDK.
Founded Year Domain Location
Simulation software is developed for chemoinformatics and drug discovery.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by DILIsym

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - DILIsym

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Dilisym Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of DILIsym

DILIsym operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, HotSpot Therapeutics, TOLREMO therapeutics, Certara and Inpharmatica, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
An AI-enabled platform is developed for infectious disease treatment.
domain founded_year HQ Location
Developer of a platform for protein function analysis
domain founded_year HQ Location
Anti-cancer small molecules are developed to target drug resistance pathways.
domain founded_year HQ Location
Provider of a platform for in silico drug discovery and consulting services
domain founded_year HQ Location
Developer of predictive informatics based platform for drug discovery
domain founded_year HQ Location
Immune system-based drugs are discovered via biological data analytics.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Dilisym

Frequently Asked Questions about DILIsym

When was DILIsym founded?

DILIsym was founded in 2014 and raised its 1st funding round 5 years after it was founded.

Where is DILIsym located?

DILIsym is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.

Who is the current CEO of DILIsym?

Brett Howell is the current CEO of DILIsym.

What does DILIsym do?

Founded in 2014 and based in Durham, United States, DILIsym operates in the pharmaceutical software sector. Quantitative toxicology tools are offered to model drug-induced liver injuries and predict patient-specific toxicities. Hazards from individual drug molecules are analyzed through an in silico graphical interface, supporting investigations into compounds, doses, and durations. Integration with the companys SimPops platform enables simulation of inter-individual variability in drug responses across virtual patient populations.

Who are the top competitors of DILIsym?

DILIsym's top competitors include Insitro, HotSpot Therapeutics and Certara.

Who are DILIsym's investors?

DILIsym has 2 investors. Key investors include Simulations Plus, and National Institute of Diabetes and Digestive and Kidney Diseases.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available